Ziopharm, Intrexon collaborate on DNA-based oncology therapeutics
Under the agreement, Ziopharm will use Intrexon’s UltraVector Technology to develop and commercialize DNA-based therapeutics. Ziopharm will utilize Intrexon’s advanced transgene engineering platform to facilitate the controlled and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.